MARC Record from marc_columbia

LEADER: 03264cam a22004213 4500
001 7932344
005 20221201045254.0
008 100630t20102010xx 000 0 eng d
020 $a9781607618027
020 $a1607618028
035 $a(OCoLC)ocn646113643
035 $a(OCoLC)646113643
035 $a(NNC)7932344
035 $a7932344
040 $aBTCTA$beng$cBTCTA$dYDXCP$dSCB$dNNC-M
245 00 $aAnticoagulants, Antiplatelets, and Thrombolytics /$cedited by Shaker A. Mousa.
260 $aNew York, N.Y. :$bHumana Press,$c[2010], ©2010.
300 $axi, 316 pages :$billustrations ;$c27 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
490 1 $aSpringer Protocols
490 1 $aMethods in molecular biology,$x1940-6029 ;$v663
504 $aIncludes bibliographical references and index.
505 0 $aIn vitro methods of evaluating antithrombotics and thrombolytics / S.A. Mousa -- In vivo models for the evaluation of antithrombotics and thrombolytics / S.A. Mousa -- Heparin and low-molecular weight heparins in thrombosis and beyond / S.A. Mousa -- Laboratory methods and management of patients with heparin-induced thrombocytopenia / M. Prechel, W.P. Jeske and J.M. Walenga -- Novel anticoagulant therapy: Principle and practice / S.A. Mousa -- Oral direct factor xa inhibitors, with special emphasis on rivaroxaban / S.A. Mousa -- Antiplatelet therapies: Drug interactions in the management of vascular disorders / S.A. Mousa -- Prasugrel: A novel platelet adp p2y(12) receptor antagonist / S.A. Mousa, W.P. Jeske and J. Fareed -- Antithrombotic effects of naturally derived products on coagulation and platelet function / S.A. Mousa -- Assessment of anti-metastatic effects of anticoagulant and antiplatelet agents using animal models of experimental lung metastasis / A. Amirkhosravi ... [et al.] -- Adhesion molecules: Potential therapeutic and diagnostic implications / S.A. Mousa -- Pharmacogenomics in thrombosis / S.A. Mousa -- Diagnosis and management of sickle cell disorders / S.A. Mousa and M.H. Qari.
650 0 $aAnticoagulants (Medicine)$0http://id.loc.gov/authorities/subjects/sh85005656
650 0 $aBlood platelets.$0http://id.loc.gov/authorities/subjects/sh85015006
650 0 $aThrombolytic therapy.$0http://id.loc.gov/authorities/subjects/sh91000682
650 0 $aFibrinolytic agents.$0http://id.loc.gov/authorities/subjects/sh85048033
650 12 $aAnticoagulants$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D000925Q000627
650 12 $aThrombolytic Therapy$xmethods.$0https://id.nlm.nih.gov/mesh/D015912Q000379
650 22 $aFibrinolytic Agents$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D005343Q000627
650 22 $aHeparin$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D006493Q000627
650 22 $aPlatelet Aggregation Inhibitors$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D010975Q000627
650 22 $aThrombocytopenia$xdrug therapy.$0https://id.nlm.nih.gov/mesh/D013921Q000188
720 $aMoussa, Shakar A.
830 0 $aSpringer protocols (Series)$0http://id.loc.gov/authorities/names/no2008180772
830 0 $aMethods in molecular biology (Clifton, N.J.) ;$vv. 663.$0http://id.loc.gov/authorities/names/n92002874
852 00 $boff,hsl$hQH506$i.M56 v.663